FindTrial
Sign In

A prospective registration study of checkpoint inhibitors in the treatment of liver injury induced by primary liver cancer

A prospective registration study of checkpoint inhibitors in the treatment of liver injury induced by primary liver cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043092
Enrollment
Unknown
Registered
2021-02-05
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

According to the severity of liver injury to develop treatment:Nil

Sponsors

Beijing You'an Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Any age or gender; 2) Imaging and/or pathological diagnosis of primary hepatocellular carcinoma; 3) Treatment with immune checkpoint inhibitors; 4) Sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Combined with autoimmune liver disease; 2) Malignant tumors of other systems; 3) Those who cannot cooperate to complete the follow-up; 4) Severe liver damage, CHILD grade C.

Design outcomes

Primary

MeasureTime frame
Liver function;—

Countries

China

Contacts

Public ContactZhangjing

Beijing You'an Hospital, Capital Medical University

drzhangjing@163.com+86 13391859683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026